Advertisement

Do statins prevent Alzheimer's disease? A narrative review

Published:September 02, 2015DOI:https://doi.org/10.1016/j.ejim.2015.08.012

      Highlights

      • Cholesterol-related pathways might play a role in development of Alzheimer's disease.
      • Cholesterol may accelerate the production of the Alzheimer's-related amyloid Aβ.
      • Statins are beneficial in preventing heart disease in high-risk populations.
      • Statins have multiple effects far beyond their cholesterol and lipid-lowering properties.
      • Currently, statins cannot be recommended for Alzheimer's disease prevention.

      Abstract

      Alzheimer's disease is the most common cause of dementia and occurs commonly in patients 65 and older. There is an urgent need to find an effective management that could help prevent or at least slow down the progress of this major public health problem. Cholesterol related pathways might play a role in the pathogenesis of Alzheimer's disease. Treatment with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) has been suggested to promote the prevention of Alzheimer's disease. In this review, we discuss potential pathogenetic pathways for the development of Alzheimer's disease and review the evidence regarding the value of statins as a strategy to prevent or delay progression of Alzheimer's disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • de la Torre J.C.
        Alzheimer disease as a vascular disorder: nosological evidence.
        Stroke. 2002; 33: 1152-1162
        • Gorelick P.B.
        • William M.
        Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors.
        Stroke. 2005; 36: 875-879
      1. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs.
        7/3/2012
        • Jukema J.W.
        • Cannon C.P.
        • de Craen A.J.
        • Westendorp R.G.
        • Trompet S.
        The controversies of statin therapy: weighing the evidence.
        J Am Coll Cardiol. 2012; 60: 875-881
      2. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
        Circulation. 2002; 106: 3143-3421
        • Wilson P.W.
        • D'Agostino R.B.
        • Levy D.
        • Belanger A.M.
        • Silbershatz H.
        • Kannel W.B.
        Prediction of coronary heart disease using risk factor categories.
        Circulation. 1998; 97: 1837-1847
        • Stamler J.
        • Wentworth D.
        • Neaton J.D.
        Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
        JAMA. 1986; 256: 2823-2828
        • Mihos C.G.
        • Salas M.J.
        • Santana O.
        The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review.
        Cardiol Rev. 2010; 18: 298-304
        • Brown M.S.
        • Goldstein J.L.
        A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood.
        Proc Natl Acad Sci U S A. 1999; 96: 11041-11048
        • Bayorh M.A.
        • Ganafa A.A.
        • Eatman D.
        • Walton M.
        • Feuerstein G.Z.
        Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
        Am J Hypertens. 2005; 18: 1496-1502
        • Park J.K.
        • Muller D.N.
        • Mervaala E.M.
        • Dechend R.
        • Fiebeler A.
        • Schmidt F.
        • et al.
        Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.
        Kidney Int. 2000; 58: 1420-1430
        • Moncada S.
        • Higgs E.A.
        Nitric oxide and the vascular endothelium.
        in: Handbook of experimental pharmacology. 176 Pt 1. 2006: 213-254
        • Cirino G.
        • Fiorucci S.
        • Sessa W.C.
        Endothelial nitric oxide synthase: the Cinderella of inflammation?.
        Trends Pharmacol Sci. 2003; 24: 91-95
        • Rosenson R.S.
        • Tangney C.C.
        • Casey L.C.
        Inhibition of proinflammatory cytokine production by pravastatin.
        Lancet. 1999; 353: 983-984
        • Pahan K.
        • Sheikh F.G.
        • Namboodiri A.M.
        • Singh I.
        Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages.
        J Clin Invest. 1997; 100: 2671-2679
        • Tuomisto T.T.
        • Lumivuori H.
        • Kansanen E.
        • Hakkinen S.K.
        • Turunen M.P.
        • van Thienen J.V.
        • et al.
        Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2.
        Cardiovasc Res. 2008; 78: 175-184
        • Pignatelli P.
        • Sanguigni V.
        • Lenti L.
        • Loffredo L.
        • Carnevale R.
        • Sorge R.
        • et al.
        Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin.
        J Thromb Haemost. 2007; 5: 1170-1178
        • McCullough P.A.
        • Silver M.A.
        • Kennard E.D.
        • Kelsey S.F.
        • Michaels A.D.
        • Investigators I.
        Impact of body mass index on outcomes of enhanced external counterpulsation therapy.
        Am Heart J. 2006; 151: 139
        • Colli S.
        • Eligini S.
        • Lalli M.
        • Camera M.
        • Paoletti R.
        • Tremoli E.
        Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.
        Arterioscler Thromb Vasc Biol. 1997; 17: 265-272
        • Tong X.K.
        • Lecrux C.
        • Rosa-Neto P.
        • Hamel E.
        Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits.
        J Neurosci Off J Soc Neurosci. 2012; 32: 4705-4715
        • Sosa-Ortiz A.L.
        • Acosta-Castillo I.
        • Prince M.J.
        Epidemiology of dementias and Alzheimer's disease.
        Arch Med Res. 2012; 43: 600-608
        • Prince M.
        • Bryce R.
        • Albanese E.
        • Wimo A.
        • Ribeiro W.
        • Ferri C.P.
        The global prevalence of dementia: a systematic review and metaanalysis.
        Alzheimers Dement. 2013; 9 ([e2]): 63-75
        • Musiek E.S.
        • Holtzman D.M.
        Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.
        Curr Opin Neurol. 2012; 25: 715-720
        • Markowitsch H.J.
        • Staniloiu A.
        Amnesic disorders.
        Lancet. 2012; 380: 1429-1440
        • Giannakopoulos P.
        • Duc M.
        • Gold G.
        • Hof P.R.
        • Michel J.P.
        • Bouras C.
        Pathologic correlates of apraxia in Alzheimer disease.
        Arch Neurol. 1998; 55: 689-695
        • Akiyama H.
        • Barger S.
        • Barnum S.
        • Bradt B.
        • Bauer J.
        • Cole G.M.
        • et al.
        Inflammation and Alzheimer's disease.
        Neurobiol Aging. 2000; 21: 383-421
        • Miao J.
        • Xu F.
        • Davis J.
        • Otte-Holler I.
        • Verbeek M.M.
        • Van Nostrand W.E.
        Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein.
        Am J Pathol. 2005; 167: 505-515
        • Poirier J.
        • Davignon J.
        • Bouthillier D.
        • Kogan S.
        • Bertrand P.
        • Gauthier S.
        Apolipoprotein E polymorphism and Alzheimer's disease.
        Lancet. 1993; 342: 697-699
        • Farrer L.A.
        • Cupples L.A.
        • Haines J.L.
        • Hyman B.
        • Kukull W.A.
        • Mayeux R.
        • et al.
        Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.
        JAMA. 1997; 278: 1349-1356
        • Myers R.H.
        • Schaefer E.J.
        • Wilson P.W.
        • D'Agostino R.
        • Ordovas J.M.
        • Espino A.
        • et al.
        Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study.
        Neurology. 1996; 46: 673-677
        • Pfrieger F.W.
        Cholesterol homeostasis and function in neurons of the central nervous system.
        Cell Mol Life Sci. 2003; 60: 1158-1171
        • Lloyd-Jones D.M.
        • Wilson P.W.
        • Larson M.G.
        • Leip E.
        • Beiser A.
        • D'Agostino R.B.
        • et al.
        Lifetime risk of coronary heart disease by cholesterol levels at selected ages.
        Arch Intern Med. 2003; 163: 1966-1972
        • Refolo L.M.
        • Malester B.
        • LaFrancois J.
        • Bryant-Thomas T.
        • Wang R.
        • Tint G.S.
        • et al.
        Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.
        Neurobiol Dis. 2000; 7: 321-331
        • Fassbender K.
        • Simons M.
        • Bergmann C.
        • Stroick M.
        • Lutjohann D.
        • Keller P.
        • et al.
        Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.
        Proc Natl Acad Sci U S A. 2001; 98: 5856-5861
        • Puglielli L.
        • Tanzi R.E.
        • Kovacs D.M.
        Alzheimer's disease: the cholesterol connection.
        Nat Neurosci. 2003; 6: 345-351
        • Jick H.
        • Zornberg G.L.
        • Jick S.S.
        • Seshadri S.
        • Drachman D.A.
        Statins and the risk of dementia.
        Lancet. 2000; 356: 1627-1631
        • Cramer C.
        • Haan M.N.
        • Galea S.
        • Langa K.M.
        • Kalbfleisch J.D.
        Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.
        Neurology. 2008; 71: 344-350
        • Sparks D.L.
        • Kryscio R.J.
        • Sabbagh M.N.
        • Connor D.J.
        • Sparks L.M.
        • Liebsack C.
        Reduced risk of incident AD with elective statin use in a clinical trial cohort.
        Curr Alzheimer Res. 2008; 5: 416-421
        • Haag M.D.
        • Hofman A.
        • Koudstaal P.J.
        • Stricker B.H.
        • Breteler M.M.
        Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study.
        J Neurol Neurosurg Psychiatry. 2009; 80: 13-17
        • Swiger K.J.
        • Manalac R.J.
        • Blumenthal R.S.
        • Blaha M.J.
        • Martin S.S.
        Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects.
        Mayo Clin Proc. 2013; 88: 1213-1221
        • Arvanitakis Z.
        • Schneider J.A.
        • Wilson R.S.
        • Bienias J.L.
        • Kelly J.F.
        • Evans D.A.
        • et al.
        Statins, incident Alzheimer disease, change in cognitive function, and neuropathology.
        Neurology. 2008; 70: 1795-1802
        • Shepherd J.
        • Blauw G.J.
        • Murphy M.B.
        • Bollen E.L.
        • Buckley B.M.
        • Cobbe S.M.
        • et al.
        Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
        Lancet. 2002; 360: 1623-1630
        • Heart Protection Study Collaborative G
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Prince M.J.
        • Macdonald A.M.
        • Sham P.C.
        • Richards M.
        • Quraishi S.
        • Horn I.
        The development and initial validation of a telephone-administered cognitive test battery (TACT).
        Int J Methods Psychiatr Res. 1999; 8: 49-57
        • McGuinness B.
        • Craig D.
        • Bullock R.
        • Passmore P.
        Statins for the prevention of dementia.
        Cochrane Database Syst Rev. 2009; 2: CD003160